Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H28N4O3 |
Molecular Weight | 396.4827 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=C(CC2=NC3=C(C=CC(=C3)[N+]([O-])=O)N2CCN(CC)CC)C=C1
InChI
InChIKey=PXDBZSCGSQSKST-UHFFFAOYSA-N
InChI=1S/C22H28N4O3/c1-4-24(5-2)13-14-25-21-12-9-18(26(27)28)16-20(21)23-22(25)15-17-7-10-19(11-8-17)29-6-3/h7-12,16H,4-6,13-15H2,1-3H3
Molecular Formula | C22H28N4O3 |
Molecular Weight | 396.4827 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Etonitazene is a potent and selective mu-opioid agonist. It was developed in CIBA. Administration of etonitazene may induce respiratory depression, and therefor etonitazene is not used in humans. Etonitazene is explicitly listed as an illegal drug under UN convention and is illegal throughout the world.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979 |
0.5 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979 |
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9537678
In rat tail-withdrawal assay, etonitazene was administered subcutaneously. ED50 was 0.38 mg/kg.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2167979
Binding of etonitazene to mu-opioid receptors from the membrane fraction of rat brains (minus cerebellum) was studied using [3H]DAMGO as a radioligand. Etonitazene binds to mu-opioid receptors with Ki of 0.5 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:10:57 GMT 2023
by
admin
on
Fri Dec 15 16:10:57 GMT 2023
|
Record UNII |
9U3GT3353T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
9624
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
||
|
NCI_THESAURUS |
C241
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Etonitazene
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ETONITAZENE
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
DB01462
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
m5197
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | Merck Index | ||
|
13493
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
100000082109
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
C084835
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
9U3GT3353T
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
1073
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
CHEMBL312040
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
SUB07334MIG
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
911-65-9
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
C65596
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
DTXSID6048919
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY | |||
|
213-009-1
Created by
admin on Fri Dec 15 16:10:58 GMT 2023 , Edited by admin on Fri Dec 15 16:10:58 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
TARGET -> AGONIST |
Emax=134% of Fentanyl
EC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|